DAFNA Capital Management’s Corbus Pharmaceuticals CRBP Stock Holding History

DAFNA Capital Management’s Portfolio CRBP Stock Details CRBP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-3,602	Closed	-$907K	–	83
2020 Q2	$907K	Sell	3,602 -21,308	-86%	-$4.31M	0.26%	60
2020 Q1	$3.92M	Buy	24,910 +15,000	+151%	+$2.54M	1.63%	18
2019 Q4	$1.62M	Hold	9,910	–	–	0.56%	44
2019 Q3	$1.45M	Hold	9,910	–	–	0.54%	48
2019 Q2	$2.06M	Sell	9,910 -257	-3%	-$55K	0.77%	36
2019 Q1	$2.12M	Buy	10,167 +5,000	+97%	+$1.1M	0.91%	33
2018 Q4	$905K	Buy	+5,167	New	+$1.03M	0.45%	51
2016 Q3	–	Sell	-13,333	Closed	-$1.2M	–	85
2016 Q2	$1.2M	Buy	+13,333	New	+$1.05M	0.95%	38
2015 Q4	–	Sell	-1,667	Closed	-$79K	–	80
2015 Q3	$79K	Buy	1,667 +447	+37%	+$29.8K	0.08%	83
2015 Q2	$113K	Buy	+1,220	New	+$123K	0.1%	72

Other funds holding CRBP

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EMG

ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

SG Americas Securities New York $92.9B AUM 36.98% 1-Year Est. Return

DAFNA Capital Management's CRBP Position: Q3 2020 in Review

DAFNA Capital Management sold out of Corbus Pharmaceuticals (CRBP) in Q3 2020, closing a stake of 3,602 shares — an estimated $907K sold.

DAFNA Capital Management first reported a position in CRBP in Q2 2015 and held it in 10 quarters. The position peaked at $3.92M in Q1 2020. 122 funds tracked by Wall St. Rank hold CRBP as of Q3 2020.

DAFNA Capital Management reported no remaining Corbus Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
DAFNA Capital Management sold 3,602 Corbus Pharmaceuticals shares in Q3 2020, an estimated $907K.
DAFNA Capital Management first reported a position in Corbus Pharmaceuticals in Q2 2015 and held it in 10 quarters.
DAFNA Capital Management's Corbus Pharmaceuticals position peaked at $3.92M in Q1 2020.
122 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q3 2020.

Based on DAFNA Capital Management's 13F filing for Q3 2020, filed 16 Nov 2020.